Gilead Sciences Shows Strong Growth Driven by HIV and Liver Disease Portfolios
Gilead Sciences (GILD) reported a strong third quarter, with total revenue increasing 7% year-over-year to $8.3 billion. Despite significant declines in COVID-19 medicine sales (Veklury) and cell therapy, the company's core HIV franchise saw an 18% increase in sales, reaching $6.2 billion. This growth was primarily driven by Biktarvy and Descovy. The company also reported a 13% rise in its liver disease portfolio revenue. Recent regulatory approvals for products such as Bixlenvo, Hepcludex, and label expansions for Trodelvy are expected to bolster medium-term financial results. While oncology remains a secondary focus with mixed historical success, Gilead's extensive oncology pipeline offers potential for future diversification beyond its dominant HIV business.
Tickers: $GILD
Topics: Biotechnology Financial Performance HIV Therapeutics Revenue Growth
Read the full article at Motley Fool
Part of the story Gilead Sciences Shows Strong Growth Driven by HIV and Liver Disease Portfolios (4 articles)